[Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
Prulifloxacin (PUFX), a new quinolone antimicrobial agent, was administered to a total of 122 patients and carriers to investigate its clinical efficacy, safety and usefulness in infectious enteritis (bacillary dysentery, enteritis caused by Salmonella spp. and enteropathogenic E. coli, cholera and so on). In addition, the minimum inhibitory concentration (MIC) of UFX (active compound) was determined against each clinical isolate, and compared with that of ciprofloxacin (CPFX), ofloxacin (OFLX), tosufloxacin (TFLX) and nalidixic acid (NA). The correlation between the concentration of UFX in feces and the change of the fecal microflora were also investigated when PUFX was administered to the patients with acute infectious enteritis. A daily dose of 400 mg of PUFX was administered orally in two divided doses (morning and evening) for 5 days, with the exception of 7 days administration against salmonella enteritis and 3 days administration against cholera. 84 cases were adapted for evaluating the usefulness. The clinical efficacy was 100% in all the enteritis except salmonella enteritis, in which it was 88.9% (8/9 cases). On the bacteriological efficacy, the elimination rate was 100% in all isolates except Salmonella spp., in which it was 75.0% (12/16 cases). As for the adverse effect, uriticaria in moderate degree was observed in 1 (0.9%) of 109 cases. Abnormal changes in laboratory findings were seen in 3 (3.0%) of 100 cases, consisting of 1 with eosinophilia and 2 with elevated S-GPT, although they were all slight in degree. The usefulness rate was 65.5% (55/84 cases) for "very useful" and 95.2% (80/84 cases) for "very useful" and "useful". MIC90 of UFX against Shigella spp., Salmonella spp., E. coli and V. cholerae, was 0.025, 0.05, 0.025 and 0.05 microgram/ml, respectively. These values were the same as those of CPFX and TFLX, and superior to OFLX and NA. UFX concentrations in feces followed by administration of PUFX in 3 cases with acute infectious enteritis were higher than that of MIC90 of UFX against Shigella spp., Salmonella spp., E. coli and V. cholerae. The changes of the fecal microflora, which influence the efficacy and safety of PUFX, were not observed.
Tomizawa
I
I
Department of Infectious Diseases, Minamigaoka Branch of Sapporo City General Hospital.
Takizawa
Y
Y
Nitta
Y
Y
Tsunoda
T
T
Fukuda
H
H
Yamaguchi
T
T
Masuda
G
G
Negishi
M
M
Ajisawa
A
A
Murata
M
M
Ohnishi
K
K
Irimajiri
S
S
Obana
M
M
Sajima
Y
Y
Sagara
H
H
Kato
H
H
Hosoda
S
S
Banba
T
T
Sasaki
M
M
Yoshikawa
K
K
Nakagawa
M
M
Ohkubo
H
H
Kim
Y
Y
Akao
M
M
Fukuyama
M
M
D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D004148:Dioxolanes / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004751:Enteritis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D010879:Piperazines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D015363:Quinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D000890:Anti-Infective Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; C074191:prulifloxacin